MYLAN-DARUNAVIR DIN 02437422
Health Canada record
| Active ingredient(s) | DARUNAVIR 75 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AE10 DARUNAVIR |
| Original market date | |
| Current status date | 27-Jan-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Mylan Pharmaceuticals ULC — licence 101774, currently licensed, last inspection rating C (2026-02-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DARUNAVIR
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02487241 | APO-DARUNAVIR | APOTEX INC | Tablet | DARUNAVIR 600 MG | Marketed |
| 02487268 | APO-DARUNAVIR | APOTEX INC | Tablet | DARUNAVIR 800 MG | Marketed |
| 02521334 | DARUNAVIR | JAMP PHARMA CORPORATION | Tablet | DARUNAVIR 400 MG | Approved |
| 02521350 | DARUNAVIR | JAMP PHARMA CORPORATION | Tablet | DARUNAVIR 800 MG | Marketed |
| 02504448 | MAR-DARUNAVIR | MARCAN PHARMACEUTICALS INC | Tablet | DARUNAVIR 400 MG | Approved |
| 02504464 | MAR-DARUNAVIR | MARCAN PHARMACEUTICALS INC | Tablet | DARUNAVIR 800 MG | Approved |
| 02504456 | MAR-DARUNAVIR | MARCAN PHARMACEUTICALS INC | Tablet | DARUNAVIR 600 MG | Approved |
| 02521342 | DARUNAVIR | JAMP PHARMA CORPORATION | Tablet | DARUNAVIR 600 MG | Dormant |
| 02522292 | M-DARUNAVIR | MANTRA PHARMA INC | Tablet | DARUNAVIR 800 MG | Cancelled Post Market |
| 02522276 | M-DARUNAVIR | MANTRA PHARMA INC | Tablet | DARUNAVIR 400 MG | Cancelled Pre Market |
| 02522284 | M-DARUNAVIR | MANTRA PHARMA INC | Tablet | DARUNAVIR 600 MG | Cancelled Post Market |
| 02437430 | MYLAN-DARUNAVIR | MYLAN PHARMACEUTICALS ULC | Tablet | DARUNAVIR 150 MG | Cancelled Pre Market |
| 02437449 | MYLAN-DARUNAVIR | MYLAN PHARMACEUTICALS ULC | Tablet | DARUNAVIR 300 MG | Cancelled Pre Market |
| 02437457 | MYLAN-DARUNAVIR | MYLAN PHARMACEUTICALS ULC | Tablet | DARUNAVIR 400 MG | Cancelled Pre Market |
| 02437465 | MYLAN-DARUNAVIR | MYLAN PHARMACEUTICALS ULC | Tablet | DARUNAVIR 600 MG | Cancelled Pre Market |
| 02459426 | MYLAN-DARUNAVIR | MYLAN PHARMACEUTICALS ULC | Tablet | DARUNAVIR 800 MG | Cancelled Pre Market |
| 02506912 | NAT-DARUNAVIR | NATCO PHARMA (CANADA) INC | Tablet | DARUNAVIR 800 MG | Cancelled Pre Market |
| 02506904 | NAT-DARUNAVIR | NATCO PHARMA (CANADA) INC | Tablet | DARUNAVIR 600 MG | Cancelled Pre Market |
| 02506890 | NAT-DARUNAVIR | NATCO PHARMA (CANADA) INC | Tablet | DARUNAVIR 400 MG | Cancelled Pre Market |
| 02519666 | SANDOZ DARUNAVIR | SANDOZ CANADA INCORPORATED | Tablet | DARUNAVIR 800 MG | Cancelled Pre Market |
| 02519658 | SANDOZ DARUNAVIR | SANDOZ CANADA INCORPORATED | Tablet | DARUNAVIR 600 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 23068 | 2020-01-02 | Abbreviated New Drug Submission (ANDS) |
International API supply for DARUNAVIR
25 active FDA Drug Master Files.
Request a quote for MYLAN-DARUNAVIR